These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22783173)

  • 1. Mathematical insights into the effects of levodopa.
    Reed MC; Nijhout HF; Best JA
    Front Integr Neurosci; 2012; 6():21. PubMed ID: 22783173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted manipulation of serotonergic neurotransmission affects the escalation of aggression in adult male Drosophila melanogaster.
    Alekseyenko OV; Lee C; Kravitz EA
    PLoS One; 2010 May; 5(5):e10806. PubMed ID: 20520823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A bacterial cellulose-based LiSrVO
    Mahdavi M; Emadi H; Nabavi SR
    Nanoscale Adv; 2023 Sep; 5(18):4782-4797. PubMed ID: 37705795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin as a biomarker of toxin-induced Parkinsonism.
    Buchanan AM; Mena S; Choukari I; Vasa A; Crawford JN; Fadel J; Maxwell N; Reagan L; Cruikshank A; Best J; Nijhout HF; Reed M; Hashemi P
    Mol Med; 2024 Mar; 30(1):33. PubMed ID: 38429661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson's disease.
    Nagatsu T; Nakashima A; Watanabe H; Ito S; Wakamatsu K; Zucca FA; Zecca L; Youdim M; Wulf M; Riederer P; Dijkstra JM
    J Neural Transm (Vienna); 2023 May; 130(5):611-625. PubMed ID: 36939908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multi-Scale Computational Model of Levodopa-Induced Toxicity in Parkinson's Disease.
    Muddapu VR; Vijayakumar K; Ramakrishnan K; Chakravarthy VS
    Front Neurosci; 2022; 16():797127. PubMed ID: 35516806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions.
    Nair SS; Muddapu VR; Chakravarthy VS
    Front Comput Neurosci; 2021; 15():756881. PubMed ID: 35046787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized Medicine to Improve Treatment of Dopa-Responsive Dystonia-A Focus on Tyrosine Hydroxylase Deficiency.
    Nygaard G; Szigetvari PD; Grindheim AK; Ruoff P; Martinez A; Haavik J; Kleppe R; Flydal MI
    J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A model of dopamine and serotonin-kynurenine metabolism in cortisolemia: Implications for depression.
    Dalvi-Garcia F; Fonseca LL; Vasconcelos ATR; Hedin-Pereira C; Voit EO
    PLoS Comput Biol; 2021 May; 17(5):e1008956. PubMed ID: 33970902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An integrative model of Parkinson's disease treatment including levodopa pharmacokinetics, dopamine kinetics, basal ganglia neurotransmission and motor action throughout disease progression.
    Véronneau-Veilleux F; Robaey P; Ursino M; Nekka F
    J Pharmacokinet Pharmacodyn; 2021 Feb; 48(1):133-148. PubMed ID: 33084988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoreceptor control of serotonin dynamics.
    Best J; Duncan W; Sadre-Marandi F; Hashemi P; Nijhout HF; Reed M
    BMC Neurosci; 2020 Sep; 21(1):40. PubMed ID: 32967609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications.
    Miguelez C; Benazzouz A; Ugedo L; De Deurwaerdère P
    Front Cell Neurosci; 2017; 11():274. PubMed ID: 28955204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's Disease.
    Roberts P; Spiros A; Geerts H
    Front Pharmacol; 2016; 7():6. PubMed ID: 26869923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated dopaminergic neuronal model with reduced intracellular processes and inhibitory autoreceptors.
    Cullen M; Wong-Lin K
    IET Syst Biol; 2015 Dec; 9(6):245-58. PubMed ID: 26577159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using mathematical models to understand metabolism, genes, and disease.
    Nijhout HF; Best JA; Reed MC
    BMC Biol; 2015 Sep; 13():79. PubMed ID: 26400419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A network model of basal ganglia for understanding the roles of dopamine and serotonin in reward-punishment-risk based decision making.
    Balasubramani PP; Chakravarthy VS; Ravindran B; Moustafa AA
    Front Comput Neurosci; 2015; 9():76. PubMed ID: 26136679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noradrenergic terminals regulate L-DOPA-derived dopamine extracellular levels in a region-dependent manner in Parkinsonian rats.
    Navailles S; Milan L; Khalki H; Di Giovanni G; Lagière M; De Deurwaerdère P
    CNS Neurosci Ther; 2014 Jul; 20(7):671-8. PubMed ID: 24775184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voltammetric and mathematical evidence for dual transport mediation of serotonin clearance in vivo.
    Wood KM; Zeqja A; Nijhout HF; Reed MC; Best J; Hashemi P
    J Neurochem; 2014 Aug; 130(3):351-9. PubMed ID: 24702305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting dopaminergic effects of L-DOPA in the treatment for Parkinson's disease.
    Navailles S; Di Giovanni G; De Deurwaerdère P
    CNS Neurosci Ther; 2014 Jul; 20(7):699-701. PubMed ID: 24628826
    [No Abstract]   [Full Text] [Related]  

  • 20. Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls.
    Herbert MK; Kuiperij H; Bloem BR; Verbeek MM
    J Neurol; 2013 Dec; 260(12):3129-33. PubMed ID: 24122060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.